Amyris (NASDAQ:AMRS) is scheduled to be announcing its earnings results after the market closes on Thursday, March 15th. Analysts expect the company to announce earnings of $0.07 per share for the quarter.
Amyris (NASDAQ AMRS) opened at $5.80 on Tuesday. The firm has a market capitalization of $249.60, a PE ratio of -0.94 and a beta of 0.38. Amyris has a 52 week low of $1.86 and a 52 week high of $10.65. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78.
Several equities analysts have recently weighed in on AMRS shares. HC Wainwright set a $15.00 price objective on Amyris and gave the company a “buy” rating in a research note on Wednesday, November 29th. ValuEngine raised Amyris from a “strong sell” rating to a “sell” rating in a research note on Friday, February 23rd. B. Riley started coverage on Amyris in a research note on Thursday, January 25th. They issued a “buy” rating and a $8.00 price objective on the stock. Cowen reaffirmed a “hold” rating and issued a $4.00 price objective on shares of Amyris in a research note on Wednesday, November 29th. Finally, Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $7.69.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.